Katherine Tuttle, MD, is Executive Director for Research at Providence Inland Northwest Health and Professor of Medicine at the University of Washington.

From FLOW to REMODEL: Understanding Semaglutide in CKD, With Katherine Tuttle, MD

Chronic kidney disease (CKD) in the setting of type 2 diabetes represents one of the most high-risk clinical scenarios in medicine, driven not only by progression to kidney failure but by a substantial burden of cardiovascular morbidity and premature death.

While recent therapeutic advances have improved outcomes, understanding how these treatments exert their benefits has remained a critical gap. The REMODEL trial was designed to address this question, offering a detailed mechanistic complement to landmark outcome data on semaglutide’s benefit in this patient population.

 at the World Congress of Nephrology (WCN) in Yokohama, Japan, Katherine Tuttle, MD, explained that REMODEL builds on the success of the FLOW trial, which demonstrated significant reductions in kidney events, cardiovascular outcomes, and all-cause mortality with semaglutide, ultimately leading to the agent’s US Food and Drug Administration approval for this indication. While those findings established clinical efficacy, they did not fully explain the underlying biology. REMODEL, she explains, was specifically designed as a mechanistic “deep dive,” integrating advanced imaging, kidney biopsy, and transcriptomic analyses to uncover how these benefits are achieved.

The study confirmed key clinical findings, including a 40% reduction in albuminuria and stabilization of kidney function. Of note, functional MRI revealed significant reductions in kidney fat far exceeding overall weight loss as well as improved vascular health, reflected by decreased renal arterial resistance. Markers of fibrosis progression were halted in the treatment group, suggesting a protective structural effect.

Biopsy data provided further depth. Tuttle highlights a marked reduction in peri-glomerular immune cells, particularly natural killer T cells, alongside broad downregulation of fibroinflammatory pathways, pointing to a direct anti-inflammatory effect within the kidney microenvironment. Transcriptomic analyses additionally identified glomerular endothelial cells as a key site of regulation, supporting the concept of improved integrity of the glomerular filtration barrier and even evidence of repair, not just stabilization, over time.

She emphasizes that these results align closely with preclinical models, strengthening confidence in translational research approaches. Beyond individual findings, the study design itself represents a major advance, demonstrating that rigorous mechanistic trials can be successfully conducted in humans.

Looking ahead, Tuttle underscores the implications for precision medicine. While current therapies are broadly applied, variability in response remains a major challenge. By linking mechanistic signatures to treatment outcomes, REMODEL provides a framework for identifying responders and tailoring therapy. Ultimately, she suggests, this approach could shift care toward selecting the right treatment for the right patient at the right time, marking a significant step forward in the management of diabetic kidney disease.

Editors’ note: relevant disclosures for Tuttle include Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio, Novo Nordisk, Travere Therapeutics, and Bayer.

Campbell P. Semaglutide 1.0 mg (Ozempic) Reduced Kidney Events 24% in FLOW Trial. HCPLive. March 5, 2024. Accessed March 31, 2026. 

https://www.hcplive.com/view/semaglutide-1-0-mg-ozempic-reduced-kidney-events-24-in-flow-trial

Brooks A. FDA Approves Semaglutide (Ozempic) for Type 2 Diabetes, Chronic Kidney Disease. HCPLive. January 28, 2025. Accessed March 31, 2026. 

https://www.hcplive.com/view/fda-approves-semaglutide-ozempic-type-2-diabetes-chronic-kidney-disease

Pruijm M, Belmar N, Bjornstad P, et al. REMODELing mechanistic trials for kidney disease: a multimodal, tissue-centered approach to understand the renal mechanism of action of semaglutide. 

Videos

REMODEL reveals how semaglutide protects kidneys, showing reduced inflammation, improved vascular health, and evidence of structural repair in diabetic CKD.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

TRACE: Tralokinumab Data for Atopic Dermatitis in Skin of Color, With April Armstrong, MD, MPH

A new post-hoc analysis from the TRACE study suggests 80.4% of patients with skin of color and atopic dermatitis who were involved in the study achieved at least 1 clinically meaningful disease control endpoint at 12 months of use.

This post-hoc analysis was 1 of several from the TRACE study presented at the 

2026 American Academy of Dermatology (AAD) Annual Meeting

. The data was authored by investigators such as April Armstrong, MD, MPH, of UCLA’s David Geffen School of Medicine, who spoke with 

 about these new findings on tralokinumab, providing important real-world insights into the long-term effectiveness of tralokinumab in adults with atopic dermatitis.

“The TRACE study is a real world study looking at patients with moderate to severe atopic dermatitis who started on tralokinumab, and the unique aspect about this particular study is that it recruited globally and [used] a patient population,” Armstrong explained.

The study is a prospective, non-interventional, international study designed to assess outcomes over 12 months in those using tralokinumab in routine clinical practice. In 1 piece of data highlighted at the meeting, patients with baseline head and neck involvement (n=495) saw substantial and sustained disease improvement over time.

Specifically, the proportion of those reporting any head and neck involvement dipped from baseline to 46.3% at Month 3 and dipped further to 31.6% at Month 12. The investigators noted such improvements were accompanied by early and clinically meaningful gains in symptom burden and disease severity, including reductions in Peak Pruritus and Sleep Numerical Rating Scale (PP/Sleep-NRS) scores, Investigator’s Global Assessment (IGA) scores, and Dermatology Life Quality Index (DLQI) score improvements.

In the separate subgroup analysis described by Armstrong, regarding 131 patients with skin of color (Fitzpatrick skin types IV–VI), 80.4% attained at least a single clinically meaningful disease control endpoint by the 12-month mark. These endpoints included IGA 0/1, EASI ≤7, or SCORAD <10, suggesting minimal to mild disease. Observance of quality of life improvements also took place in this population.

“What we found is that, among patients who were classified as skin of color, about 80% of them are able to achieve that stringent endpoint by 12 months,” Armstrong said. “And importantly, for that particular endpoint looking at the difference between, for example, patients who are skin of color with the overall population, the difference was actually very small.”

Across the overall study population (n=824), Armstrong et al found 91% of patients achieved at least 1 moderate treatment target after 12 months of tralokinumab use. Notably, approximately three-quarters met both clinician-reported and patient-reported moderate endpoints. The team also found nearly half attained optimal targets consistent with minimal disease activity.

For any additional information on these data, view Armstrong’s full interview posted above.

The quotes used in this summary were edited for clarity.

Armstrong has served as a consultant for and received honoraria from AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Eli Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun, and UCB and has participated in advisory boards for Boehringer Ingelheim and Parexel.

LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026. LEO Pharma. May 30, 2026. 

https://www.businesswire.com/news/home/20260328143419/en/LEO-Pharma-Presents-New-12-Month-Real-World-Data-for-Tralokinumab-at-AAD-2026

Armstrong AW, Rubin C, Jarell A, et al. Real-world effectiveness of 12 months tralokinumab treatment in patients with skin of color and moderate-to-severe atopic dermatitis: final data from the prospective, non-interventional, international TRACE study. Presented at the 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO. Poster ID: 77199. Oral Poster Presentation.

This interview highlights new 12-month, real-world data on tralokinumab and its long-term efficacy in patients with skin of color who live with atopic dermatitis.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Thierry Passeron, MD, PhD, is a professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

Upadacitinib Safe, Effective Over 48 Weeks for Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Upadacitinib is both safe and effective over 48 weeks among patients with 

, new findings suggest, with no new safety signals or major adverse cardiovascular events (MACE) identified.

These late-breaking data, the result of the Viti-Up-1 and Viti-Up-2 studies, were released during the 

 editorial team spoke on-site with trial investigator Thierry Passeron, MD, PhD, professor and chair of the Department of Dermatology at the Université Côte d'Azur in Nice, France.

“Unfortunately, so far, there is no systemic treatment approved for vitiligo, and there is still a high unmet need for the patients suffering from vitiligo,” Passeron explained.

Non-segmental vitiligo, an autoimmune inflammatory disease impacting the skin, is characterized by patients’ loss of melanocytes. This can lead to unpredictable skin depigmentation. Passeron stressed the lack of systemic medications approved for the condition, describing additional options as necessary.

Passeron and colleagues reported in this study on the efficacy and safety of upadacitinib, a selective once-daily Janus kinase (JAK) 1 inhibitor, 15 mg in adults and adolescents with non-segmental vitiligo. It was studied across 48 weeks in this pair of identical, pivotal phase 3 analyses.

In his interview, Passeron noted most of the patients were Fitzpatrick skin types 3 and 4, further describing those treated with upadacitinib in the study as being a severe disease population. The subjects were both adults and adolescents aged ≥ 12 years with this skin disease involving the face and body.

They all had a Facial Vitiligo Scoring Index (F-VASI) ≥ 0·5 and a Total Vitiligo Area Scoring Index (T-VASI) ≥ 5. The subjects were randomized 2:1 to be treated either with upadacitinib 15 mg or placebo once daily. There were 614 individuals involved across Viti-Up-1 (n=308) and Viti-Up-2 (n=306) in total.

“Two-thirds of the population were active, and three-fourths had T-VASI above 10…and the mean duration of the vitiligo was about 15 years,” Basseron said. “Most of them had vitiligo that had already been treated by topical treatment of phototherapy.”

In this poster at AAD, the treatment with upadacitinib was described as providing clinically meaningful repigmentation among adult and adolescent patients with non-segmental vitiligo.

 Passeron and coauthors’ safety data through week 48 were described as consistent with the overall profile for upadacitinib.

Specifically, they noted a lack of reports of adjudicated MACE, adjudicated gastrointestinal (GI) perforations, adjudicated venous thromboembolic events (VTE), lymphoma, active tuberculosis, non-melanoma skin cancer, or opportunistic infections outside of herpes zoster in either analysis.

 Among the most often reported TEAEs, examples included acne, upper respiratory infection, nasopharyngitis, and headache. There were 4 serious infections reported among patients in the Viti-Up-1 upadacitinib cohort, though none led to treatment cessation.

For any additional information on the new data from the Viti-Up-1 and 2 trials, view the full video with Passeron posted above.

Passeron is a consultant for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Calypso, Galderma, Incyte Corporation, Janssen, Eli Lilly, Novartis, Pfizer, Roivant, UCB, and VYNE Therapeutics. He has received grants and/or honoraria from AbbVie, ACM Pharma, Almirall, Amgen, Astellas, Bristol Myers Squibb, Calypso, Celgene, Galderma, Genzyme/Sanofi, GlaxoSmithKline, Incyte Corporation, Janssen, LEO Pharma, Eli Lilly, Novartis, Pfizer, Roivant, Sun Pharmaceuticals, Takeda, UCB, and VYNE Therapeutics. He is the cofounder of NIKAIA Pharmaceuticals and founder of SUNLUTION, and has patents on WNT agonists or GSK3b antagonist for repigmentation of vitiligo and the use of CXCR3B blockers in vitiligo.

Passeron T, Prajapati V, Seneschal J, et al. Efficacy and Safety of Upadacitinib in Adolescents and Adults for Treatment of Non-Segmental Vitiligo: Results of Two Phase 3 Studies (Viti-Up). Presented at: 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO.

Smith T. Upadacitinib Regulatory Applications Submitted for Adults, Adolescents with Vitiligo. HCPLive. February 3, 2026. Accessed March 30, 2026. 

https://www.hcplive.com/view/upadacitinib-regulatory-applications-submitted-adults-adolescents-vitiligo

Patients with non-segmental vitiligo (NSV) on upadacitinib versus placebo showed continuous improvement over 48 weeks with no plateau.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Dominic Sisti, PhD, is an associate professor in the Department of Medical Ethics & Health Policy and the director of the Scattergood Program for the Applied Ethics of Behavioral Health Care. Sisti is also the host of 

, our monthly multimedia series on medical ethics in modern healthcare. 

Richard Miller, MD, staff psychiatrist at Elwyn Adult Behavioral Health in Cranston, Rhode Island.

Your Patient's New Therapist Is an AI. Now What?

Watch the full expert dynamic feature above.

In your clinic, you may hear patients say, “Chat told me this” or “Chat told me that.” Numerous individuals use ChatGPT, colloquially referred to as “Chat,” to get quick, convenient 

advice. This can be dangerous, depending on what the chatbot says, potentially providing patients with advice you would never, in a million years, give.

“More often, it's actually deleterious where information is cherry-picked, and the context is not always understood,” said Richard Miller, MD, a staff psychiatrist at Elwyn Adult Behavioral Health in Cranston, RI. “Patients are kind of going on an extended trip…to get the information that they're looking for…. maybe [a] particular answer. It's not always accurate.”

Despite the danger, AI can also be helpful in the psychiatry field. AI can provide a new perspective and can augment, not replace, treatment.

 Editorial Team put together a feature examining the benefits, dangers, and ethics surrounding AI use in psychiatry. Millions of Americans struggle to access mental health care, with waitlists sometimes lasting 3 to 6 months.

These individuals, desperate for mental health advice, turn to AI. As Darlene King, MD, from the University of Texas Southwest Medical Center, said, using AI as a therapist is like getting mental health advice from a friend, who can very well give bad advice.

Dominic Sisti, PhD, from Penn Medicine, discussed the ethical concerns of AI in psychiatry. Vulnerable populations may be susceptible to abusing AI and can even go as far as asking ChatGPT ways to self-harm. “How would these AI platforms [respond] to a patient who is indicating they have suicidal ideation or behavior?” he asked. “How might these platforms recognize elevated risk for self-harm or harm to others?

Sisti stressed the need for guardrails on age restrictions, redirection protocols, and HIPAA compliance standards. He also said there is a need for platforms to distinguish between an investigator asking about suicide methods versus someone in crisis.

Other than mental health advice, AI can assist in screening. In 2024, a study showed the promise of Sonde Health’s mental fitness vocal biomarker tool to 

identify depression from the sound of a voice

 Another study showed the potential of MoodCapture, a smartphone application using AI to 

detect the onset of depression based on facial cues 

More recently, a study showed AI can predict treatment response in major depressive disorder (MDD). In the 

phase 2b OLIVE trial assessing BH-200 (nelivaptan)

, a selective vasopressin V1b receptor antagonist, a proprietary genetic tool stratified patients by vasopressin-related biomarkers.

 Patients with lower peripheral but higher central vasopressin activity had a stronger antidepressant response, supporting biomarker-guided patient selection.

AI can also help with psychiatrists’ day-to-day responsibilities. For instance, Suki AI, Heidi, and DeepScribe, among others, are designed for clinician documentation.

As AI becomes more commonplace, experts recommend asking about its use non-judgmentally during routine history-taking. Although potentially dangerous, AI can be beneficial if used with a “human in the loop,” according to Sisti.

 Staff psychiatrist at Elwyn Adult Behavioral Health in Cranston, RI.

Associate professor of medical ethics & health policy, director of the scattergood program for applied ethics in behavioral health care, associate professor of psychiatry (secondary), associate professor of philosophy (secondary) at the University of Pennsylvania.

Assistant professor in the department of psychiatry at University of Texas Southwest Medical Center who specializes in general adult psychiatry, including women’s health, addiction, and trauma.

A psychiatrist and chief medical officer at HMNC Brain Health.

Andrew. How Long Is the Wait to See a Psychiatrist? What to Expect and How to Shorten It. Brain Health USA. Published September 30, 2025. 

https://brainhealthusa.com/how-long-is-the-wait-to-see-a-psychiatrist/

Derman C. A Voice Detecting Depression? Lindsey Venesky, PhD, Discusses New Data. HCPLive. March 14, 2024. Accessed on March 30, 2026. 

https://www.hcplive.com/view/a-voice-detecting-depression-lindsey-venesky-phd-discusses-new-data

Derman, C. Smartphone App with AI Detects Depression Onset from Facial Expressions. HCPLive. February 28, 2024. Accessed March 30, 2026. 

https://www.hcplive.com/view/smartphone-app-ai-detects-depression-onset-facial-expressions

Eriksson H. New Genetic Tool Shows Promise for Targeted MDD Treatment, With Hans Eriksson, PhD, MD. HCPLive. Published December 5, 2026. Accessed March 30, 2026. 

https://www.hcplive.com/view/new-genetic-tool-shows-promise-targeted-mdd-treatment-hans-eriksson-md-phd

Palm E, Manikantan A, Mahal H, Belwadi SS, Pepin ME. Assessing the quality of AI-generated clinical notes: validated evaluation of a large language model ambient scribe. 

. 2025;8:1691499. Published 2025 Oct 22. 

Mess SA, Mackey AJ, Yarowsky DE. Artificial Intelligence Scribe and Large Language Model Technology in Healthcare Documentation: Advantages, Limitations, and Recommendations. 

. 2025;13(1):e6450. Published 2025 Jan 16. 

DeepScribe. DeepScribe Solidifies Ambient AI Leadership in Oncology with New Study and Accelerated Growth. Prnewswire.com. Published September 16, 2025. Accessed March 30, 2026. 

https://www.prnewswire.com/news-releases/deepscribe-solidifies-ambient-ai-leadership-in-oncology-with-new-study-and-accelerated-growth-302557045.html

As patients increasingly turn to ChatGPT for mental health support, psychiatrists and ethicists weigh the clinical risks, ethical concerns, and what clinicians should do next.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Schizophrenia

The HCPLive schizophrenia page is a resource for medical news and expert insights on the mental disorder. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for schizophrenia, and more.

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

Joseph Rossano, MD
Credit: American College of Cardiology

A phase 3 randomized trial found mavacamten (Camzyos) significantly reduced left ventricular outflow tract (LVOT) obstruction in adolescents with symptomatic 

obstructive hypertrophic cardiomyopathy (oHCM)

The findings from the SCOUT-HCM trial were presented as a late-breaking clinical trial at the 

American College of Cardiology's Annual Scientific Session (ACC.26)

 and, according to Bristol Myers Squibb, represent the first prospective phase 3 evidence for a cardiac myosin inhibitor in a pediatric oHCM population.

“Pediatric HCM is a rare cardiac disorder that is associated with severe, sometimes life-threatening, symptoms,” said principal investigator Joseph Rossano, MD, chief of the Division of Cardiology at Children’s Hospital of Philadelphia.

 “With no approved therapies for pediatric patients with oHCM and current recommendations for pharmacological therapy primarily extrapolated from evidence obtained from adult studies, the positive results of this trial represent a significant advance in the field of pediatric cardiology and the potential for a meaningful new therapy for adolescent patients if approved by the FDA.”

SCOUT-HCM was a double-blind, randomized, placebo-controlled phase 3 trial enrolling adolescents aged 12 to less than 18 years with NYHA class II or III oHCM across 28 sites in 9 countries. Eligible patients had a Valsalva LVOT gradient of 30 mm Hg or greater, a maximal LVOT gradient of 50 mm Hg or greater, and a left ventricular ejection fraction (LVEF) of 60% or greater. Patients with HCM phenocopies such as Noonan syndrome or Fabry disease were excluded.

Of 65 patients screened, 44 were randomized 1:1 to mavacamten or placebo for 28 weeks. The 23 patients in the mavacamten group and 21 in the placebo group had a mean age of approximately 14.7 years, 83% to 86% were on background beta-blocker therapy, and approximately half carried a pathogenic or likely pathogenic HCM mutation.

Investigators pointed out the mean baseline Valsalva LVOT gradient was 78.4 mmHg in the mavacamten group and 80.8 mmHg in the placebo group. Additionally, mavacamten was initiated at 5 mg once daily for most patients, with dose adjustment permitted based on echocardiographic assessment.

The primary endpoint was the change from baseline to week 28 in Valsalva LVOT gradient. Secondary outcomes of interest included the change from baseline to week 28 in resting and postexercise LVOT gradients, the maximal left ventricular wall thickness, and the ratio of early mitral inflow velocity to mitral annular early diastolic velocity (E/e′ ratio).

48 mmHg Reduction in Valsalva LVOT Gradient

At week 28, the least-squares mean change in Valsalva LVOT gradient was -48.5 mmHg in the mavacamten group versus -0.5 mm Hg in the placebo group, a between-group difference of -48.0 mmHg (95% CI, -67.7 to -28.3; 

Analysis of secondary outcomes of interest also favored mavacamten, including reductions in resting LVOT gradient (difference, -47.0 mm Hg; 95% CI, -62.7 to -31.4), postexercise LVOT gradient (difference, -41.7 mm Hg; 95% CI, -59.7 to -23.7), maximal LV wall thickness (difference, -1.8 mm; 95% CI, -3.4 to -0.2), and average E/e' ratio (difference, -3.4; 95% CI, -5.1 to -1.6). Investigators also called attention to exploratory analyses pointing to reductions in NT-proBNP and high-sensitivity cardiac troponin levels with mavacamten.

Overall adverse event rates were similar between groups (78% mavacamten vs 81% placebo). Serious adverse events occurred in 2 patients per arm. A single patient in the mavacamten group had 2 episodes of syncope deemed related to study drug and another had an inappropriate ICD shock considered unrelated. No patient in either group died or experienced an LVEF below 50%, and no cases of atrial fibrillation or symptomatic heart failure were reported.

Investigators highlighted several key limitations in their study to consider. These included the small sample size, restriction to ages 12 and older, a predominantly White study population, and the 28-week placebo-controlled follow-up period.

“The SCOUT-HCM results underscore the potential for [mavacamten] to become the first CMI for adolescents, reinforcing our leadership in the CMI space and our role in reshaping the scientific understanding of oHCM and how the disease is diagnosed, evaluated and potentially treated,” said Cristian Massacesi, MD, executive vice president, chief medical officer, and head of development at Bristol Myers Squibb.

 “With these meaningful safety and efficacy data, we are excited about the potential to provide a paradigm-changing treatment for adolescents and their families.”

Rossano JW, Canter C, Wolf CM, et al. Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. 

. Published online March 29, 2026. Accessed March 30, 2026. doi:

Bristol Myers Squibb. Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). Bms.com. Published March 29, 2026. Accessed March 30, 2026. 

https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Presents-Positive-Results-from-Phase-3-SCOUT-HCM-Trial-Demonstrating-Efficacy-and-Safety-of-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM/default.aspx

Articles

New information from the phase 3 SCOUT-HCM trial indicate the benefits of mavacamten may extend to adolescents as well as adults. 

Cardiomyopathy

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Mavacamten Shows Benefit for Pediatric Patients in SCOUT-HCM Trial

Chovatiya discussed new data showing significant EASI improvements across moderate and severe atopic dermatitis.

REZOLVE-AD: Rezpegaldesleukin Shows Consistent Efficacy Across Atopic Dermatitis Severity, With Raj Chovatiya, MD, PhD

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

Results from the phase 3 trial were published in NEJM and simultaneously presented as a late-breaking abstract at AAD 2026.

VALOR: Brepocitinib AAD Data Support Priority Review for Dermatomyositis

Nicholas Marston, MD, MPH, is a cardiologist and an assistant professor of medicine at Brigham and Women's Hospital.

Marston discusses his sub analysis of the VESALIUS-CV trial, which indicated reduced MACE risk in patients with diabetes and no atherosclerosis after evolocumab treatment.

Atherosclerotic Cardiovascular Disease

Strategic Alliance Partnership

Evolocumab Reduces CV Risk in Non-Atherosclerotic Patients With Diabetes, With Nicholas Marston, MD, MPH

Layla Van Doren, MD, MBA, is an assistant professor of medicine at Yale School of Medicine and a classical hematologist at Smilow Cancer Hospital.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Burnout in Sickle Cell Physicians Hits 60% While Grit and Resilience Stand Strong

Linda Stein Gold, MD, is a dermatologist at Henry Ford Health. 

Video Series

Evaluating Treatment Selection in Psoriasis

Luisa Campos, Global Heme Lead, Medical & Scientific Affairs at Thermo Fisher Scientific.

Rapid NGS and streamlined workflows are critical to delivering timely, actionable genomic insights in blood cancers, but access, reimbursement, and expertise gaps persist.

Timing Is Everything: Advancing Genomic Testing in Hematologic Malignancies

Understanding the Psoriasis Treatment Landscape and Available IL-23 Inhibitors

This interview with David Cotter, MD, PhD, highlights recent findings and new data in the psoriasis treatment space highlighted at AAD 2026.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

AAD Updates on Risankizumab and More for Psoriasis, With David Cotter, MD, PhD

Alessia Fornoni, MD, PhD, is a Professor of Medicine, Molecular and Cellular Pharmacology, and Biochemistry at the University of Miami Miller School of Medicine and Director and Chair of the Peggy and Harold Katz Drug Discovery Center.

NEPTUNE and CureGN are advancing precision nephrology, linking molecular data to outcomes and enabling targeted therapies and smarter clinical trial design.

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

​​NEPTUNE and CureGN Driving Precision Nephrology Forward, With Alessia Fornoni, MD, PhD

CAR-T therapy in lupus may shift earlier in care, but challenges in access, logistics, and patient selection remain as the field moves toward precision treatment.

Latest News

From FLOW to REMODEL: Understanding Semaglutide in CKD, With Katherine Tuttle, MD

TRACE: Tralokinumab Data for Atopic Dermatitis in Skin of Color, With April Armstrong, MD, MPH

Upadacitinib Safe, Effective Over 48 Weeks for Non-Segmental Vitiligo, With Thierry Passeron, MD, PhD

Your Patient's New Therapist Is an AI. Now What?

Mavacamten Shows Benefit for Pediatric Patients in SCOUT-HCM Trial